Cancer Stem Cell Market Size Grows at a CAGR of 9.03%

Introduction

Straits Research released its highly anticipated report, “Global Cancer Stem Cell Market Size & Outlook, 2026-2034.” According to the study, the global market size is valued at USD 3.03 billion in 2025 and is projected to expand to USD 6.58 billion by 2034, registering a compound annual growth rate (CAGR) of 9.03%.

Market Dynamics

The growth of the global cancer stem cell market is primarily driven by the rising incidence of cancer worldwide, coupled with increasing awareness of cancer recurrence and metastasis risks associated with conventional therapies. As global cancer prevalence continues to rise, so does the need for advanced treatment approaches that target CSCs, the key drivers of tumor relapse and resistance. According to the National Cancer Institute’s SEER Cancer Stat Facts Report, approximately 2 million new cancer cases are projected to be diagnosed in the U.S. in 2025, including around 316,950 women and 2,800 men with breast cancer, the most common malignancy. Such an escalating cancer burden is fostering strong demand for CSC-based research and therapeutic innovations. Moreover, technological advancements and scientific discoveries in CSC biology are creating significant opportunities for novel drug development.

However, the high cost and complexity associated with CSC research, along with limited clinical validation of CSC-targeted therapies, act as key restraints to market growth. The intricate nature of CSC isolation, characterization, and targeting poses challenges in large-scale drug development and commercialization. On the other hand, growing collaborations between biotechnology firms, academic institutions, and pharmaceutical companies, coupled with increasing investment in CSC-targeted drug discovery, are expected to accelerate market expansion.

Market Highlights

• Mode of Action: The stem cell-based cancer therapy segment is estimated to grow at a CAGR of 9.71% during the forecast period.
• Cancer Type: The lung cancer segment is projected to grow at the fastest pace with a CAGR of 11.23% during 2026-2034.
• Regional Insights: North America dominated the global market with a market share of 41.38% in 2025, owing to a surge in product approvals of advanced therapies.

Competitive Players

1. AbbVie, Inc.
2. Merck KGaA
3. Bionomics
4. Lonza
5. The Menarini Group
6. Miltenyi Biotec
7. PromoCell GmbH
8. MacroGenics, Inc.
9. OncoMed Pharmaceuticals, Inc.
10. FUJIFILM Irvine Scientific
11. STEMCELL Technologies
12. Sino Biological, Inc.
13. Lineage Cell Therapeutics, Inc.
14. Celprogen Inc.
15. AstraZeneca
16. Gilead Sciences
17. Bristol Myers Squibb
18. FibroBiologics
19. Others

Recent Developments

Segmentation

1. By Mode of Action (2022-2034)
   1. Targeted Cancerous Stem Cells (CSCs)
      1. By Anti-CSC Therapeutics
         1. Pathway Inhibitors
         2. Immuno-evasion & Targeting Tumor Microenvironment
         3. Nanoparticle-based Therapies
         4. Others
      2. By Products
         1. Cell-Culturing
         2. Cell-Separation
         3. Cell Analysis
         4. Molecular Analysis
         5. Others
   2. Stem Cell-based Cancer Therapy
      1. Autologous SC Transplant
      2. Allogeneic SC Transplant
2. By Cancer Types (2022-2034)
   1. Breast
   2. Blood
   3. Lung
   4. Brain
   5. Colorectal
   6. Pancreatic
   7. Bladder
   8. Liver
   9. Others